About PetMed Express, Inc.
https://www.1800petmeds.comPetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses.
CEO
Caroline Conegliano
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1999-03-04 | Forward | 3:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 42
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:1.61M
Value:$5.62M
RENAISSANCE TECHNOLOGIES LLC
Shares:1.27M
Value:$4.43M
VANGUARD GROUP INC
Shares:964.05K
Value:$3.36M
Summary
Showing Top 3 of 119
About PetMed Express, Inc.
https://www.1800petmeds.comPetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $44.36M ▼ | $20.8M ▲ | $-8.52M ▲ | -19.2% ▲ | $-0.41 ▲ | $-5.91M ▲ |
| Q1-2026 | $51.18M ▲ | $18.99M ▼ | $-34.15M ▼ | -66.73% ▼ | $-1.65 ▼ | $-31.66M ▼ |
| Q4-2025 | $46.47M ▼ | $24.97M ▲ | $-11.64M ▼ | -25.06% ▼ | $-0.56 ▼ | $-2.75M ▼ |
| Q3-2025 | $52.98M ▼ | $15.36M ▼ | $-707K ▼ | -1.33% ▼ | $-0.03 ▼ | $1.14M ▼ |
| Q2-2025 | $59.57M | $16.76M | $2.33M | 3.9% | $0.11 | $2.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $36.1M ▼ | $100.3M ▼ | $57.24M ▼ | $43.06M ▼ |
| Q1-2026 | $41.13M ▼ | $109.84M ▼ | $58.29M ▼ | $51.55M ▼ |
| Q4-2025 | $54.72M ▲ | $148.7M ▲ | $63.57M ▲ | $85.13M ▼ |
| Q3-2025 | $50.1M ▼ | $144.79M ▼ | $48.61M ▼ | $96.18M ▼ |
| Q2-2025 | $52.05M | $146.03M | $49.6M | $96.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-31.03M ▲ | $-21.46M ▼ | $-1.53M ▼ | $-256K ▼ | $-18.62M ▼ | $-22.98M ▼ |
| Q1-2026 | $-34.15M ▼ | $-12.27M ▼ | $-1.29M ▲ | $-30K ▼ | $-13.59M ▼ | $-13.56M ▼ |
| Q4-2025 | $-11.64M ▼ | $7.01M ▲ | $-2.39M ▼ | $-5K ▼ | $4.62M ▲ | $4.62M ▲ |
| Q3-2025 | $-707K ▼ | $-1.17M ▼ | $-777K ▲ | $-1K ▲ | $-1.94M ▼ | $-1.94M ▼ |
| Q2-2025 | $2.33M | $7.39M | $-1.26M | $-71K | $6.05M | $6.12M |
CEO
Caroline Conegliano
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1999-03-04 | Forward | 3:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 42
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:1.61M
Value:$5.62M
RENAISSANCE TECHNOLOGIES LLC
Shares:1.27M
Value:$4.43M
VANGUARD GROUP INC
Shares:964.05K
Value:$3.36M
Summary
Showing Top 3 of 119